Active or currently recruiting clinical trials for inhibitors of the PI3K/AKT/mTOR pathway according to the highest phase including ovarian cancer patients, indication (± biomarkers), monotherapy or combination therapy, clinical trials and year opened. Here, PIK3CD is linked to ovarian cancer.